← Medication & Supplement Reference

VETERINARY TEAM REFERENCE · MEDICATION

Tigilanol tiglate

Updated October 27, 2026 · Sources and review status below

For veterinarians and veterinary staff. Product-label information is distinct from extra-label clinical practice. This is not a complete prescribing formulary or an automated interaction screen. Verify the current label, exact formulation, patient and species-specific clinical reference before use. Independent veterinary/pharmacy review remains pending.

Prescribing overview

Local treatment for selected non-metastatic canine mast cell tumors.

Protein kinase C-activating antineoplasticProduct-specific clinical reference

Tumor destruction leaves a wound. Extensive tissue loss and life-threatening mast cell degranulation are important labeled risks.

Key prescribing checks

  • Read the product-specific safety section and monitoring plan before selecting a treatment.

Uses by species

Approval and evidence apply to the named product, species, route and indication. An extra-label use requires its own prescribing assessment; a human indication is not an animal approval.

Dogs

US veterinary label

Non-metastatic cutaneous mast cell tumors; subcutaneous mast cell tumors at or below the elbow/hock

Stage the tumor and confirm its location before selection.

Use / indication source ↗

Pharmacology & pharmacokinetics

Mechanism and clinical role

Local cellular injury, inflammation and tumor-vessel disruption produce tumor necrosis.

Absorption, distribution, metabolism and elimination

Systemic exposure after intratumoral treatment is variable; local administration does not eliminate systemic risk.

SAFETY REFERENCE · PRODUCT & SPECIES SPECIFIC

Contraindications & cautions

Contraindications identify circumstances where the source says a product should not be used. Precautions call for assessment or monitoring. Interactions identify combinations to review. They are distinct categories; this summary does not replace a full interaction check or the current product label.

Stelfonta

US veterinary label; Intratumoral injection.

Contraindications · when not to use

  • Do not inject subcutaneous mast cell tumors above the elbow or hock.

Precautions & monitoring

  • Not intended for metastatic tumors. Evaluate wound-healing risks and mucocutaneous sites. Avoid injection beyond tumor margins.

Selected product scope; does not establish suitability for other species, routes or formulations.

Safety sources checked: . Selected label information; independent veterinary or veterinary-pharmacy review remains pending. A label for dogs, cats, horses or humans does not establish safety for another species.

Adverse effects

Pain, edema, bruising, cellulitis, extensive wounds and severe systemic degranulation can occur.

These are selected source-reported effects, not incidence estimates or an exhaustive list. Spontaneous postmarketing reports do not by themselves establish frequency or causality.

Dosing & administration

Verify the source before prescribing. The regimens below summarize selected veterinary product labels, not every accepted veterinary use. They are not automatic substitutions between brands or formulations. Renal/hepatic disease, concurrent therapy, age, indication and clinical response can require a different plan.

A verified veterinary dose has not been entered for this product. Human-label dosing must not be used as an animal regimen. Consult a current species-specific clinical source and the prescribing veterinarian.

No numeric regimen is supplied in this reference. The veterinarian must select the exact product-label protocol for the patient, indication and route; this entry does not enable an automatic dose.

Extra-label prescribing and food-animal residue requirements are separate from labeled regimens. FDA extra-label-use guidance ↗

Drug & supplement interactions

This monograph summarizes selected interactions. The comparison tool applies a curated set of rules and is not comprehensive. Reconcile prescription drugs, nonprescription products, supplements and recent treatment changes.

Compare with other medications and check species →

Stelfonta

US veterinary label; Intratumoral injection.

  • The label requires a corticosteroid plus H1 and H2 blockers; these are protective co-medications, not optional duplicate treatments.
Interaction source ↗Interaction source ↗

Monitoring

Assess systemic degranulation after treatment and wound progress until healed; severe pain, swelling or breathing changes need urgent reassessment.

Client counseling

Give every prescribed companion medicine. Prevent licking; wear gloves for wound care and report worsening illness.

This section supports the veterinary team's discharge discussion; it does not replace the product’s Client Information Sheet where one is required.

Storage & handling

Single-use vial; follow current label refrigeration and hazardous-handling instructions. Accidental self-injection can cause severe wounds.

Brands, formulations & ingredient identity

Active ingredients

Tigilanol tiglate

An intratumoral oncology product; not a routine systemic injection.

Shared ingredients do not establish interchangeable concentrations, routes, release properties, species labeling or regional availability.

Stelfonta

Formulation
Intratumoral injection
Label / product scope
Dogs

Stage the tumor and confirm its location before selection.

Product label / source ↗

References & review status

Clinical reference updated October 27, 2026. Independent veterinary or veterinary-pharmacy review not yet completed. Evidence gaps remain explicitly identified; this page does not claim equivalence to a comprehensive, professionally reviewed veterinary formulary.

Search another medication or supplement →

CONTINUE EXPLORING

Use these connected guides to prepare informed questions for your veterinary team.

Find Veterinary Care Near YouLocate general practices, urgent-care clinics, emergency hospitals and specialists.Read resource →When It Is an EmergencyRecognize signs that require immediate veterinary care.Read resource →Interactive Symptom NavigatorStart with what you notice and understand when to seek help.Read resource →Poisons and Household HazardsRecognize common exposures and avoid unsafe home treatment.Read resource →Printable Owner ToolkitBring observations, medication details and questions to your appointment.Read resource →
Privacy & cookie choices